PL2164516T3 - Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach - Google Patents

Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach

Info

Publication number
PL2164516T3
PL2164516T3 PL08773954T PL08773954T PL2164516T3 PL 2164516 T3 PL2164516 T3 PL 2164516T3 PL 08773954 T PL08773954 T PL 08773954T PL 08773954 T PL08773954 T PL 08773954T PL 2164516 T3 PL2164516 T3 PL 2164516T3
Authority
PL
Poland
Prior art keywords
antibody
yield
fusion proteins
protein sequence
improve quality
Prior art date
Application number
PL08773954T
Other languages
English (en)
Inventor
Winfried S Wels
Benjamin Dälken
Sylvia E Schwarz
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07013750A external-priority patent/EP2014301A1/en
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Publication of PL2164516T3 publication Critical patent/PL2164516T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08773954T 2007-07-13 2008-07-10 Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach PL2164516T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94958007P 2007-07-13 2007-07-13
EP07013750A EP2014301A1 (en) 2007-07-13 2007-07-13 Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
PCT/EP2008/005632 WO2009010228A1 (en) 2007-07-13 2008-07-10 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
EP08773954A EP2164516B9 (en) 2007-07-13 2008-07-10 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins

Publications (1)

Publication Number Publication Date
PL2164516T3 true PL2164516T3 (pl) 2011-05-31

Family

ID=39768606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08773954T PL2164516T3 (pl) 2007-07-13 2008-07-10 Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach

Country Status (6)

Country Link
EP (1) EP2164516B9 (pl)
AU (1) AU2008277936A1 (pl)
CY (1) CY1111104T1 (pl)
HR (1) HRP20110070T1 (pl)
PL (1) PL2164516T3 (pl)
WO (1) WO2009010228A1 (pl)

Also Published As

Publication number Publication date
HRP20110070T1 (hr) 2011-03-31
AU2008277936A1 (en) 2009-01-22
EP2164516B9 (en) 2011-05-18
WO2009010228A1 (en) 2009-01-22
EP2164516A1 (en) 2010-03-24
CY1111104T1 (el) 2015-06-11
EP2164516B1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
AU2009347206A8 (en) Isolation and purification of antibodies using Protein A affinity chromatography
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2007097812A3 (en) Therapeutic anti-her2 antibody fusion polypeptides
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
EP2304440A4 (en) NEW MONOCLONAL ANTIBODIES AGAINST HPV PROTEINS
IL207762A0 (en) Purified immunoglobulin fusion proteins and methods of their purification
WO2008132568A3 (en) Fusion proteins binding to growth factors
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
ZA201202720B (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK2061897T3 (da) Fed-batch-fermenteringsproces med høj celledensitet til fremstilling af rekombinant protein
BRPI1006270A8 (pt) ''anticorpo anti a5b1, molécula de ácido nucleio isolado, célula hospedeira, método de produção de um anticorpo anti a5b1, imunoconjugado, composição farmacêutica, método de detecção de proteína a5b1, método de tratamento de um indivíduo e kit de detecção de a5b1
IL215538A0 (en) Antibody fusion proteins with modified fcrn binding sites
IL201445A0 (en) Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
GB0815576D0 (en) Analysis of glycated proteins
IL213749A0 (en) Dgati nucleic acids and proteins and methods of use thereof
WO2013070796A3 (en) Propeptide-luciferase fusion proteins and methods of use thereof
PL2164516T3 (pl) Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach
EP2197895A4 (en) METHODS AND INTERMEDIATES FOR CHEMICAL SYNTHESIS OF POLYPEPTIDES AND PROTEINS
HK1173160A (zh) B7-h4融合蛋白及其使用方法
ZA200906869B (en) Novel antibody molecules and nucleic acids binding to fungal stress protein HSP90
UA104311C2 (ru) Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7
HK1135710A (en) Human monoclonal antibodies to btla and methods of use